Short answer
LivaNova PLC (LIVN) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $391M (up 10.8% year over year) with net income of $109M.
Q2 2026 key financials · XBRL
- Revenue
- $391M
- +10.8% YoY · +7.8% QoQ
- Net income
- $109M
- +299.7% YoY · +387.0% QoQ
- Operating margin
- 12.7%
- Gross margin
- 70.1%
- EPS (diluted)
- $1.93
- +286.0% YoY · +382.5% QoQ
Source: XBRL data from the LivaNova PLC (LIVN) Q2 2026 10-Q on SEC EDGAR. USD.
LivaNova PLC Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q2 revenue $390.6M, up 10.8% YoY from $352.5M
- Gross margin 70.1% vs 67.8% YoY, with cost of sales 29.9% vs 32.2%
- Best segment Neuromodulation revenue $166.9M, up 10.1%; segment income $60.9M, up 8.8%
- Worst segment Cardiopulmonary income $28.2M, down 10.4% despite revenue up 11.2% to $221.6M
- Cash $516.6M vs $635.6M year-end; operating cash flow $81.8M, down from $86.9M, after $95.9M debt repayment
- Near-term headwinds: FX volatility, inflation, tariffs, supply-chain constraints, and potential trade restrictions
Risk Factors
- Iran sanctions-compliance exposure from sales through distributors and a nongovernmental organization
- Limited customer visibility creates potential dealings with Iranian government-owned hospitals or sub-distributors
- Iran revenue $1.8 million and net profit $0.9 million in the quarter ended June 30, 2026
- Evolving U.S., UK, and EU sanctions laws increase compliance uncertainty as LivaNova continues Iran operations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other LivaNova PLC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.